February 28, 2026
Op-Ed Authored by Lord (David) Cameron, former UK Prime Minister and Chair of the OHC Advisory Council published in The Daily Telegraph on Saturday, Feb. 28, 2026 (Rare Disease Day) Rare diseases are not actually that rare. Collectively they affect 500 million people around the world. Some, such as Huntington’s disease...
Continue Reading
February 26, 2026
The Oxford-Harrington Rare Disease Centre (OHC) highlights its commitment to driving progress for rare disease—impacting the lives of families like Cynthia Schulz and her daughter Noni who spent decades living answers or effective treatments for CASK Continue Reading
February 06, 2026
Harrington Discovery Institute at University Hospitals is supporting the development of a new drug called Zalunfiban that helped thousands of heart attack patients avoid complications in clinical trials. Continue Reading
January 29, 2026
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Continue Reading
December 23, 2025
A conversation with Matthew P. Anderson, MD, Ph.D., co-director, Oxford-Harrington Rare Disease Centre, featured in Drug Discovery Online Continue Reading
December 16, 2025
Despite the central role of p53 suppression in cancer pathogenesis, the promise of therapeutic p53 reactivation remains unrealized, with targeted and combination chemotherapies limited by efficacy, toxicity, and delivery. Continue Reading
November 14, 2025
Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune systems. Continue Reading
July 20, 2025
Published in Good News NetworkEleven years of cancer research has proven fruitful for a scientist at Johns Hopkins who uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.The new study, funded in part by the National Institutes of Health and the National Cancer... Continue Reading
July 09, 2025
Experimental Compound Offers Potential Treatment for Rare, Often Fatal, Childhood Disease Continue Reading
July 09, 2025
Decreased brain levels of coenzyme Q10 (CoQ10), an endogenously synthesized lipophilic antioxidant, underpin encephalopathy in primary CoQ10 deficiencies and are associated with common neurodegenerative diseases and the ageing process. Continue Reading
June 19, 2025
Enzymes that regulate oncogenic protein function through the addition of post-translational modifications (PTMs) represent promising targets for the development of cancer therapeutics. Continue Reading